Quantitative estimates of risk for noncancer endpoints

Risk Analysis

Volumn 25, Issue 2, 2005, Pages 285-289

  Clewell, Harvey J ^a   Crump, Kenny S ^a  

^a ENVIRON Health Sciences Institute   (United States)

Author keywords

Arsenic; Cost benefit analysis; Methylmercury; Noncancer; Quantitative risk; Risk communication

Indexed keywords

ARSENIC; COST BENEFIT ANALYSIS; DISEASE CONTROL; RISK ASSESSMENT; TUMORS;

CANCER RISK ASSESSMENTS; METHYLMERCURY; RISK COMMUNICATIONS;

BIOMEDICAL ENGINEERING;

ARSENIC; METHYLMERCURY;

CANCER; METHODOLOGY; RISK ASSESSMENT;

CANCER; CANCER RISK; COST BENEFIT ANALYSIS; DRUG EXPOSURE; HUMAN; NERVE CELL DIFFERENTIATION; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT;

EID: 18644363145     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2005.00589.x     Document Type: Review

References (23)

1. Bogdanffy, M. S., Daston, G., Faustman, E. M., Kimmel, C. A., Kimmel, G. L., Seed, J., & Vu, V. (2001). Harmonization of cancer and noncancer risk assessment: Proceedings of a consensus-building workshop. Toxicological Science, 61(1), 18-31.
2. National Research Council (NRC). (2000). Toxicological Effects of Mercury. Washington, DC: National Academies Press.
3. Goyer, R. A. (2000). Letter to JA Levitt, Director, Center for Food Safety and Applied Nutrition, Food and Drug Administration. Washington, DC: Food and Drug Administration, December 6.
4. U.S. Department of Health and Human Services (USD-HHS). (2002). The National Health and Nutrition Examination Survey (1999-2000). Available at http://www.cdc.gov/nchs/nhanes.htm.
5. Stern, A. H., & Smith, A. E. (2003). An assessment of the cord blood: Maternal blood methylmercury ratio: Implications for risk assessment. Environmental Health Perspectives, 111(12), 1465-1470.
6. Grandjean, P., Weihe, P., Jorgensen, P. J., Clarkson, T., Cernichiari, E., & Videro, T. (1992). Impact of maternal seafood diet on fetal exposure to mercury, selenium, and lead. Archives of Environmental Health, 47, 185-195.
7. U.S. Environmental Protection Agency (USEPA). (2001). National primary drinking water regulations; arsenic and clarifications to compliance and new source contaminants monitoring. Final Rule. 40 CFR Parts 141 and 142. Federal Register, 66(14), 6976-7066.
8. Chen, C. J., Chen, C. W., Wu, M. M., & Kuo, T. L. (1992). Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. British Journal of Cancer, 66(5), 888-892.
9. Chen, C. J., Choiu, H. Y., Chiang, M. H., Lin, L. J., & Tai, T. Y. (1996). Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arteriosclerosis, Thrombosis, and Vascular Biology, 16(4), 504-510.
10. Crump, K. S., Shipp, A. M., Allen, B. A., Hack, C. E., Gentry, P. R., Lawrence, G. A., Yager, J. A., & Clewell, H. C. (Submitted). Comparative benchmark analysis of the cancer and noncancer effects of inorganic arsenic. Regulatory Toxicology and Pharmacology.
11. Clewell, H. J., Barton, H., Gentry, P., Shipp, A., Yager, J., & Andersen, M. (1998). Requirements for a biologically-realistic arsenic risk assessment. International Journal of Toxicology, 18, 131-147.
12. Levy, J. I. (2003). Issues and uncertainties in estimating the health benefits of air pollution control. Journal of Toxicology and Environmental Health, Part A, 66(16-19), 1865-1871.
13. Crump, K. S., Hoel, D., Langley, C., & Peto, R. (1976). Fundamental carcinogenic processes and their implications to low dose risk assessment. Cancer Research, 36, 2973-2979.
14. U.S. Environmental Protection Agency (USEPA). (2003). Draft Final Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001A. Washington, DC: Risk Assessment Forum, USEPA.
15. Renwick, A. G. (1999). Incidence and severity in relation to magnitude of intake above the ADI or TDI: Use of critical effect data. Regulatory Toxicology and Pharmacology, 30(2 Pt. 2), S79-S86.
16. Hattis, D., Baird, S., & Goble, R. (2002). A straw man proposal for a quantitative definition of the RfD. Drug and Chemical Toxicology, 25(4), 403-436.
17. Crump, K. S., Clewell, H. J., & Andersen, M. E. (1997). Cancer and non-cancer risk assessments should be harmonized. Human and Ecological Risk Assessment, 3, 495-499.
18. Crump, K. S. (1984). A new method for determining allowable daily intakes. Fundamental and Applied Toxicology, 4(5), 854-871.
19. Gaylor, D. W. (1988). Applicability of cancer risk assessment techniques to other toxic effects. Toxicology and Industrial Health, 4(4), 453-459.
20. Teuschler, L. K., Dourson, M. L., Stiteler, W. M., McClure, P., & Tully, H. (1999). Health risk above the reference dose for multiple chemicals. Regulatory Toxicology and Pharmacology, 30, S19-S26.
21. Gaylor, D. W. (1989). Quantitative risk analysis for quantal reproductive and developmental effects. Environmental Health Perspectives, 79, 243-246.
22. Castorina, R., & Woodruff, T. J. (2003). Assessment of potential risk levels associated with U.S. Environmental Protection Agency reference values. Environmental Health Perspectives, 111(10), 1318-1325.
23. Gaylor, D. W., & Kodell, R. L. (2002). A procedure for developing risk-based reference doses. Regulatory Toxicology and Pharmacology, 35(2 Pt. 1), 137-141.